173 related articles for article (PubMed ID: 24594768)
1. [Effect of change to flutamide for prostate cancer patient who developed breast pain during bicalutamide treatment (BIP-F study)].
Kitamura Y; Okuno H; Sakura Y; Manabe Y; Masuda N; Ito H; Mishina M; Taoka R; Terai A; Sugimoto M; Kakehi Y
Hinyokika Kiyo; 2014 Jan; 60(1):17-23. PubMed ID: 24594768
[TBL] [Abstract][Full Text] [Related]
2. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years.
Iversen P; McLeod DG; See WA; Morris T; Armstrong J; Wirth MP;
BJU Int; 2010 Apr; 105(8):1074-81. PubMed ID: 22129214
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.
Fradet Y; Egerdie B; Andersen M; Tammela TL; Nachabe M; Armstrong J; Morris T; Navani S
Eur Urol; 2007 Jul; 52(1):106-14. PubMed ID: 17270340
[TBL] [Abstract][Full Text] [Related]
4. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
Di Lorenzo G; Perdonà S; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Autorino R
J Urol; 2005 Dec; 174(6):2197-203. PubMed ID: 16280763
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial.
Perdonà S; Autorino R; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Bianco AR; Di Lorenzo G
Lancet Oncol; 2005 May; 6(5):295-300. PubMed ID: 15863377
[TBL] [Abstract][Full Text] [Related]
6. Editorial comment on: Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.
Van Poppel H
Eur Urol; 2007 Jul; 52(1):115. PubMed ID: 17270341
[No Abstract] [Full Text] [Related]
7. An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients.
Bedognetti D; Rubagotti A; Conti G; Francesca F; De Cobelli O; Canclini L; Gallucci M; Aragona F; Di Tonno P; Cortellini P; Martorana G; Lapini A; Boccardo F
Eur Urol; 2010 Feb; 57(2):238-45. PubMed ID: 19481335
[TBL] [Abstract][Full Text] [Related]
8. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
Schellhammer PF; Venner P; Haas GP; Small EJ; Nieh PT; Seabaugh DR; Patterson AL; Klein E; Wajsman Z; Furr B; Chen Y; Kolvenbag GJ
J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515
[TBL] [Abstract][Full Text] [Related]
9. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
Tyrrell CJ; Iversen P; Tammela T; Anderson J; Björk T; Kaisary AV; Morris T
BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
[TBL] [Abstract][Full Text] [Related]
10. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
11. Phase I-II trial of weekly bicalutamide in men with elevated prostate-specific antigen and negative prostate biopsies.
Zanardi S; Puntoni M; Maffezzini M; Bandelloni R; Mori M; Argusti A; Campodonico F; Turbino L; Branchi D; Montironi R; Decensi A
Cancer Prev Res (Phila); 2009 Apr; 2(4):377-84. PubMed ID: 19336728
[TBL] [Abstract][Full Text] [Related]
12. [Clinical early phase II study of bicalutamide (Casodex) in patients with prostatic cancer].
Kotake T; Usami M; Isaka S; Shimazaki J; Nakano E; Okuyama A; Okajima E; Kanetake H; Saitoh Y; Kumamoto Y; Orikasa S; Sakata Y; Hosaka M; Akaza H; Koiso K; Honma Y; Aso Y; Oishi K; Yoshida O; Naitoh S; Kumazawa J; Koyanagi T; Yachiku S; Shiraiwa Y; Tsukagoshi S
Hinyokika Kiyo; 1996 Feb; 42(2):157-68. PubMed ID: 8712092
[TBL] [Abstract][Full Text] [Related]
13. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?
Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M; Penson D
Urology; 2005 Oct; 66(4):835-9. PubMed ID: 16230148
[TBL] [Abstract][Full Text] [Related]
14. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
Scher HI; Liebertz C; Kelly WK; Mazumdar M; Brett C; Schwartz L; Kolvenbag G; Shapiro L; Schwartz M
J Clin Oncol; 1997 Aug; 15(8):2928-38. PubMed ID: 9256137
[TBL] [Abstract][Full Text] [Related]
15. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
16. [Gynecomastia as a complication of hormonotherapy for prostate cancer: effect of prophylactic breast irradiation].
Abdah-Bortnyak R; Bernstein Z; Ramon N; Zalman D; Shnaider J; Kuten A
Harefuah; 2007 Feb; 146(2):126-8, 164-5. PubMed ID: 17352282
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.
Serretta V; Altieri V; Morgia G; Nicolosi F; De Grande G; Mazza R; Melloni D; Allegro R; Ferraù F; Gebbia V
Clin Genitourin Cancer; 2012 Sep; 10(3):174-9. PubMed ID: 22502790
[TBL] [Abstract][Full Text] [Related]
18. Treatment of bicalutamide-induced breast events.
Sieber PR
Expert Rev Anticancer Ther; 2007 Dec; 7(12):1773-9. PubMed ID: 18062751
[TBL] [Abstract][Full Text] [Related]
19. [A new anti-androgen, bicalutamide (Casodex), for the treatment of prostate cancer--basic clinical aspects].
Akaza H
Gan To Kagaku Ryoho; 1999 Jul; 26(8):1201-7. PubMed ID: 10431591
[TBL] [Abstract][Full Text] [Related]
20. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
Blackledge G; Kolvenbag G; Nash A
Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
